Progressive Pulmonary Fibrosis Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Progressive Pulmonary Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled372 locationsNCT06238622
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled150 locationsNCT05943535
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Not Applicable

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Fibrotic Interstitial Lungs Diseases
Katerina M. Antoniou100 enrolled1 locationNCT07466420
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled44 locationsNCT06951217
Recruiting
Not Applicable

SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

Progressive Pulmonary FibrosisInterstitial Lung Disease
Medical University of South Carolina170 enrolled1 locationNCT07269262
Recruiting

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Royal Brompton & Harefield NHS Foundation Trust30 enrolled1 locationNCT07332117
Recruiting

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Progressive Pulmonary FibrosisInterstitial Lung Disease
University of Massachusetts, Worcester500 enrolled13 locationsNCT06855329
Recruiting
Phase 1

A Trial of HRS-9813 in Healthy Subjects

Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
Guangdong Hengrui Pharmaceutical Co., Ltd60 enrolled1 locationNCT06821464
Recruiting
Phase 2

An Open-Label Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary FibrosisIPF+1 more
Avalyn Pharma Inc.340 enrolled22 locationsACTRN12625000246482
Recruiting
Phase 2

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd.110 enrolled1 locationNCT05139719